(4,6-dimethyl-pyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-one | 66177-32-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (4,6-dimethyl-pyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-one
• 英文别名: 2-(4,6-Dimethyl-pyridin-2-yl)-isoindole-1,3-dione；N-(4,6-dimethyl-pyridin-2-yl)phthalimide；N-(4,6-dimethyl-2-pyridyl)phthalimide；2-(4,6-dimethylpyridin-2-yl)isoindole-1,3-dione
• CAS: 66177-32-0
• 化学式: C₁₅H₁₂N₂O₂
• 分子量: 252.272
• InChiKey: PNZIAPKXGJPYLD-UHFFFAOYSA-N

物化性质

• 沸点：
  465.6±55.0 °C(Predicted)
• 密度：
  1.310±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  50.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4,6-dimethyl-pyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-one 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以81%的产率得到(4,6-dimethyl-pyridin-2-yl)-2,3-dihydro-3-hydroxy-1H-isoindol-1-one
  参考文献：
  名称：

  Collin; Robert; Robert-Piessard, Pharmacy and Pharmacology Communications, 1998, vol. 4, # 1, p. 27 - 31

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-4,6-二甲基吡啶 以 四氢呋喃 、 甲苯 为溶剂， 反应 76.0h， 生成 (4,6-dimethyl-pyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-one
  参考文献：
  名称：

  New anti-inflammatory N-pyridinyl(alkyl)phthalimides acting as tumour necrosis factor-α production inhibitors

  摘要：

  This paper describes the synthesis of N-pyridinyl(alkyl)phthalimides related to N-phenyl-4,5,6,7-tetrafluorophthalimides known to be inhibitors of tumour necrosis factor-alpha (TNF alpha) production. Pharmacomodulation at the phthalimidic nitrogen led to the selection of two pharmacophoric fragments (2,4-lutidinyl and beta -picolyl), allowing significant inhibition of TNF alpha production (compounds 12 and 17). Variation of the substituents linked to the homocycle of their phthalimide scaffold indicated that high (TNF alpha production) inhibitory potency could be achieved, notably by 5-fluoro, 4- or 5-nitro, 5-amino and especially tetrafluoro substitution. The most active compound, N-(pyridin-3-ylmethyl)-4,5,6,7-tetrafluorophthalimide (32) (84% inhibition at 10 muM), also produced an anti-oedematous effect in the PMA-induced mouse-ear swelling test. Although less active than dexamethasone, it exerted a marked reduction in ear thickness after oral administration (63% vs. 85% for dexamethasone at 0.2 mM kg(-1)) and remained efficient after topical application (46% vs. 96% for the dexamethasone). It also induced potent inhibition in the rat carrageenan foot oedema test with an ID50 (0.14 muM kg(-1)) comparable with that of N-(2,6-diisopropylphenyl)phthalimide (4) (0.15 muM kg(-1)). (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01254-5

文献信息

• Novel HIV reverse transcriptase inhibitors
  申请人：Guo Hongyan

  公开号：US20080070920A1

  公开（公告）日：2008-03-20

  The invention is related to compounds of Formula (I), (II), or (III): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  这项发明涉及到以下化合物的公式(I)、(II)或(III)： 或其药用可接受的盐、溶剂化合物、酯和/或膦酸酯，含有这种化合物的组合物，以及包括给予这种化合物的治疗方法。
• NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Guo Hongyan

  公开号：US20100034827A1

  公开（公告）日：2010-02-11

  The invention is related to compounds of Formula (I), (II), or (III); or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  本发明涉及公式(I)、(II)或(III)的化合物；或其药学上可接受的盐、溶剂化合物、酯和/或膦酸酯，含有这些化合物的组合物以及包括给予这些化合物的治疗方法。
• Pyrimidine-2,4-dione HIV reverse transcriptase inhibitors
  申请人：Korea Research Institute of Chemical Technology

  公开号：US08106064B2

  公开（公告）日：2012-01-31

  The invention is related to pyrimidine-2,4-dione HIV reverse transcriptase inhibitors of Formula (I), (II), or (III): or a pharmaceutically acceptable salt, thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  本发明涉及公式（I），（II）或（III）的嘧啶-2,4-二酮HIV反转录酶抑制剂，或其药学上可接受的盐，含有这种化合物的组合物，以及包括给予这种化合物的治疗方法。
• US4072499A
  申请人：——

  公开号：US4072499A

  公开（公告）日：1978-02-07
• US4124375A
  申请人：——

  公开号：US4124375A

  公开（公告）日：1978-11-07